What is it about?
Regorafenib and cabozantinib are both systemic medications used to treat late-stage liver cancer that has progressed on initial treatment. Both have shown to extend life and delay progression, together with certain side effects. Because there are no head-to-head comparisons, we do not know which of the two drugs is more effective or which one’s side effects are easier to tolerate. This paper pooled data from the randomized controlled trial for each medication to synthesize the evidence and make an indirect comparison of the two medications.
Featured Image
Photo by Nicholas Cappello on Unsplash
Why is it important?
This indirect comparison found that regorafenib leads to longer patient survival than cabozantinib, is better tolerated, and has lower risk of common side effects such as diarrhea and fatigue. This supports regorafenib as the favored choice for patients who have failed initial systemic treatment in advanced liver cancer. These findings can help guide treatment choices for patients with advanced liver cancer and improve treatment benefit, safety, and tolerability.
Read the Original
This page is a summary of: Regorafenib vs. cabozantinib as second-line treatment for advanced hepatocellular carcinoma: an anchored matching-adjusted indirect comparison of efficacy and safety, Liver Cancer, October 2022, Karger Publishers,
DOI: 10.1159/000527403.
You can read the full text:
Contributors
The following have contributed to this page
